阿斯利康AstraZeneca plc (AZN) 2004年年度报告「LSE」.pdf

1、thinkingperformanceAstraZeneca Annual Report and Form 20-F Information 2004Annual Report and Form 20-FInformation 2004AstraZeneca Annual Report and Form 20-F Information 2004ContentsThe Year in Brief01Dividend for 2004 01Chairmans Statement02Chief Executives Review04Global Market Overview06Financial

2、 Highlights07Board of Directors08Strategy10Key Products10Operational Review11Cardiovascular12Gastrointestinal15Neuroscience17Oncology20Respiratory and Inflammation23Infection25Geographic Review26Development Pipeline28Research and Development30Commercialisation and Portfolio Management31Supply and Ma

3、nufacturing32Other Businesses33Main Facilities33Corporate Responsibility34Industry Regulation35Intellectual Property36Financial Review37Directors Report52Audit Committees Report58Directors Remuneration Report60Trade marksTrade marks of the AstraZeneca group of companies appear throughout this docume

4、nt initalics.AstraZeneca,the AstraZeneca logotype and theAstraZeneca symbol are all trade marks of theAstraZeneca group of companies.Use of termsIn this Annual Report and Form 20-F Information 2004,unless the context otherwise requires,AstraZeneca,the Group,the Company,we,us and our referto AstraZen

5、eca PLC and its consolidated entities.Statements of competitive positionExcept as otherwise stated,market information in this Annual Report and Form 20-F Information 2004regarding the position of our business or productsrelative to its or their competition is based uponpublished statistical data for

6、 the 12 months ended 30 September 2004,obtained from IMS Health,aleading supplier of statistical data to thepharmaceutical industry.Except as otherwise stated,these market share and industry data from IMS Healthhave been derived by comparing our sales revenue tocompetitors and total market sales rev